Globus Medical (GMED) Secures FDA Clearances As Revenue And R And D Stay Strong
Globus Medical (GMED) has secured new FDA clearances, expanding its product offerings in spine and orthopedic surgery. This development, coupled with strong revenue growth and a steady commitment to R&D, positions the company as an innovative and high-growth investment, especially when compared to competitors like Medtronic. An analysis by Simply Wall St suggests GMED shares are currently undervalued, trading significantly below analyst targets and their estimated fair value.
Globus Medical Inc Class A Actuals & Estimates (HAM:GM0N)
This article provides actuals and estimates for Globus Medical Inc Class A (HAM:GM0N), covering financial data from income statements, balance sheets, and cash flow statements, alongside analyst forecasts. It details the company's stock performance, market capitalization, earnings, revenue, and EBITDA. The report also addresses frequently asked questions regarding its stock price, ticker, volatility, and dividend policy.
Price to sales forward of Globus Medical Inc Class A – TRADEGATE:GM0N
This article provides the "Price to sales forward" for Globus Medical Inc Class A (GM0N) on the Tradegate Exchange. It highlights the current value, change, and percentage change for this financial metric. The information is presented within the context of TradingView's financial data offerings.
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing
This article analyzes Globus Medical Inc. Class A (GMED) using AI models to provide trading strategies for different risk profiles. It highlights a strong near-term sentiment shifting to a long-term positive bias, with an impressive 53.9:1 risk-reward setup. The analysis offers specific entry, target, and stop-loss points for position trading, momentum breakout, and risk hedging strategies.
Globus Medical Inc Class A Actuals & Estimates (FWB:GM0N)
This article provides an overview of Globus Medical Inc Class A (FWB:GM0N) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It details financial actuals and estimates such as earnings per share and revenue for recent quarters, and mentions that the company does not pay dividends. Investors are advised to conduct comprehensive research before investing, considering the company’s financials, news, and technical analysis.
GM0N Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Globus Medical Inc Class A (GM0N) stock. It includes analyst ratings, earnings estimates, revenue expectations, and historical price performance, highlighting that analysts project a maximum price of 105.48 EUR and a minimum of 75.22 EUR. The company's current stock price is 72.28 EUR, and it is expected to release its next earnings report on July 30, 2026.
GM0N Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Globus Medical Inc Class A (GM0N) stock, detailing analyst opinions with a maximum estimate of 105.48 EUR and a minimum of 75.22 EUR. It covers current stock performance, historical highs and lows, volatility, market capitalization, and upcoming earnings reports, offering a comprehensive overview for potential investors. The article also includes various financial metrics and answers frequently asked questions about the company.
Globus Medical Inc Class A Actuals & Estimates (NYSE:GMED)
This article provides an overview of Globus Medical, Inc. (NYSE:GMED) stock, including its current price, performance trends, analyst forecasts, and financial data. It highlights the company's financial results, market capitalization, and upcoming earnings report, while emphasizing that the information is not investment advice.
Globus Medical Inc Class A Actuals & Estimates (BX:GMED)
This article provides an overview of Globus Medical Inc Class A (GMED) stock, including its financial actuals and estimates. It details analyst price targets, past earnings and revenue, future earnings report dates, and key financial metrics like EBITDA. The article also provides information on how to buy GMED stock and answers frequently asked questions about the company's financials and employee count.
How Globus Medical Inc. Class A (GMED) Affects Rotational Strategy Timing
This article analyzes Globus Medical Inc. Class A (GMED) from a rotational strategy perspective, highlighting a strong near-term sentiment shifting towards mid-term neutrality and long-term positive bias. It details institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and AI-generated signals for support and resistance levels. The report suggests an exceptional risk-reward setup for GMED.
Globus Medical updates guidance after NuVasive merger close, shares react on NASDAQ
Globus Medical has issued updated post-merger guidance following its all-stock acquisition of NuVasive, detailing revenue synergies, margin expectations, and integration costs for investors. The combined entity is poised to compete more directly with larger spine and orthopedics peers, benefiting from a diversified product mix. Analysts emphasize that successful integration and synergy realization will be crucial for future margin progression.
GM0N Forecast — Price Target — Prediction for 2027
This article provides a forecast for Globus Medical Inc Class A (GM0N) stock, including analyst price targets and ratings. It details the stock's current performance, historical highs and lows, volatility, market capitalization, and upcoming earnings report. The piece also answers frequently asked questions regarding GM0N's financial health and investment outlook.
GMED Forecast — Price Target — Prediction for 2027
This article provides a forecast for Globus Medical Inc Class A (GMED) stock, including analyst price targets, historical and estimated EPS and revenue, and other financial metrics. It details the stock's current price, volatility, market capitalization, upcoming earnings reports, and EBITDA. The information is presented by TradingView and includes answers to frequently asked questions about GMED.
GMED Forecast — Price Target — Prediction for 2027
This article provides a forecast for Globus Medical Inc Class A (GMED) stock, including analyst price targets, current stock performance, and financial data. It highlights the stock's recent price movements, earnings reports, revenue figures, and market capitalization, along with a disclaimer that the information is not investment advice.
Globus Medical Inc Class A Actuals & Estimates (BMV:GMED)
This article provides an overview of Globus Medical Inc Class A (GMED) stock performance, financial estimates, and analyst forecasts on the Mexican Stock Exchange. It details current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The content also addresses frequently asked questions regarding GMED's financials and investment outlook.
Price to earnings forward of Globus Medical Inc Class A – BIVA:GMED
This page displays the "Price to earnings forward" metric for Globus Medical Inc Class A (GMED) on the BIVA exchange. It indicates that the market was closed at the time of viewing, with no trades reported. The content also notes the data source and copyright information.
Globus Medical Inc Class A Actuals & Estimates (BOATS:GMED)
This article provides an overview of Globus Medical, Inc. (GMED) stock, focusing on its financial actuals and analyst estimates. It details the company's past earnings and revenue, future projections, stock price history, and key financial metrics like EBITDA. The article also confirms that GMED does not pay dividends and will release its next earnings report on July 30, 2026.
Earnings Beat Amid Currency Headwinds Might Change The Case For Investing In Globus Medical (GMED)
Globus Medical (GMED) reported better-than-expected Q1 2026 financial results, which positively influenced investor sentiment despite ongoing inflation, interest rate uncertainty, and foreign currency pressures. The company reaffirmed its full-year 2026 revenue guidance of US$3.18–3.22 billion, indicating management's effort to balance strong performance with continued external challenges. While the earnings beat supports short-term profit, investors are advised to remain vigilant regarding foreign currency and international integration risks, which could still impact long-term value.
Globus Medical (GMED) Stock Could Be 28% Undervalued Despite Recent Share Price Bounce
Globus Medical (GMED) stock has seen a recent bounce but is still down over the past month and three months. Despite a nearly 37% total shareholder return over the last year, the stock is currently perceived by some analyses as 28% undervalued, with a fair value anchored at $110 per share. This valuation hinges on the success of its robotics and digital surgery ecosystem, as well as the integration of NuVasive and Nevro.
(GMED) and the Role of Price-Sensitive Allocations
This article analyzes Globus Medical Inc. Class A (NASDAQ: GMED), noting divergent sentiment and potential for lower levels. It details AI-generated trading strategies including position, momentum, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report highlights elevated downside risk and advises on accessing real-time signals and institutional-grade analysis.
Globus Medical (GMED) Stock After 36% One-Year Gain Is There Still Upside?
Globus Medical (GMED) has seen a 36% gain over the past year, prompting an analysis of its current valuation. According to Simply Wall St's discounted cash flow (DCF) model and P/E ratio analysis, the stock appears to be significantly undervalued by approximately 49.6%. The article also introduces narratives as a way for investors to customize their valuation perspective based on factors like robotics shift, international expansion, and acquisitions.
What Globus Medical (GMED)'s Upgraded Earnings Outlook and Rising ROIC Concerns Mean For Shareholders
Globus Medical reported a strong Q1 2026 with 27% revenue growth and increased its non-GAAP EPS outlook, driven by strength in spine and enabling technologies and the Nevro acquisition integration. Despite this positive earnings momentum, the company faces rising concerns regarding its declining return on invested capital (ROIC), which questions its efficiency in sustaining profitable growth amid global expansion and new product rollouts. The article discusses how these upgraded earnings and ROIC concerns reshape Globus Medical's investment narrative, with analysts offering differing views on its future performance and fair value.
Madison Small Cap Fund Sold Globus Medical (GMED) as Valuation Exceeded
Madison Small Cap Fund liquidated its position in Globus Medical (GMED) after the company successfully integrated its Nuvasive acquisition and saw its market capitalization reach $12 billion, which exceeded the fund's intrinsic value estimate of $85 per share against a market price of $90. The fund aims to focus on smaller alternatives, despite GMED's strong revenue growth and increased hedge fund interest. Madison Small Cap Fund also notes that it believes certain AI stocks offer greater upside potential with less downside risk.
Total assets of Globus Medical Inc Class A – XETR:GM0N
The article displays the "Total assets" section for Globus Medical Inc Class A (XETR:GM0N) on TradingView. It provides a table structure with columns for "Period," "Value," "Change," and "Change %" but no specific data is populated. This page is part of the financial overview for the company on the platform.
Preferred dividends of Globus Medical Inc Class A – XETR:GM0N
This page provides information on the preferred dividends of Globus Medical Inc Class A, traded on the XETR exchange under the symbol GM0N. It is part of TradingView's financial data section, offering an overview of market data, financials, news, community insights, and forecasts for the company. The specific dividend values and changes for different periods are available on this dedicated page.
Globus Medical (NYSE: GMED) director exercises options, sells 25,000 shares
Globus Medical director David D. Davidar engaged in an exercise-and-sell transaction, exercising stock options for 25,000 shares at $26.27 each and simultaneously selling those 25,000 shares in the open market for a weighted average price of $80.7629. Following these transactions, Davidar directly holds 510,175 shares, with an additional 165,967 shares held indirectly through a family irrevocable trust. This activity is detailed in a recent Form 4 filing, outlining the specific prices and holdings.
Globus Medical (GMED) director exercises options for 25,000 new shares
Globus Medical director Ann D. Rhoads exercised stock options to acquire 25,000 shares of Class A Common Stock at $26.27 per share. These options, granted on January 30, 2017, were fully vested. Following this transaction, Ms. Rhoads now directly owns 40,384 shares of GMED, with no related share sales reported in this filing.
Tangible book value per share of Globus Medical Inc Class A – XETR:GM0N
This article provides financial information for Globus Medical Inc Class A (XETR:GM0N), specifically focusing on its tangible book value per share. The content is presented within the TradingView platform, which offers various market data and analysis tools for investors.
Pretax income of Globus Medical Inc Class A – XETR:GM0N
The article provides financial information for Globus Medical Inc Class A (XETR:GM0N), specifically focusing on its pretax income. It indicates that the market for this stock is currently closed. The data is sourced from ICE Data Services and FactSet, with SEC filings by Quartr.
Is Globus Medical’s (GMED) Robotics Leasing Shift Quietly Reshaping Its Earnings Quality?
Globus Medical (GMED) recently reported strong first-quarter results with 27% revenue growth, driven by its core spine business and expansion of its Enabling Technologies customer base. The company is shifting its Excelsius robotic platform to leasing and rental models, tied to implants and services, which could increase recurring revenue. This strategic move, along with FDA clearances, aims to enhance earnings quality, though investors should consider integration and competition risks.
Operating expenses (excl. COGS) of Globus Medical Inc Class A – XETR:GM0N
This article displays the operating expenses (excluding Cost of Goods Sold) for Globus Medical Inc Class A, traded on XETR under the symbol GM0N. It presents a data table with "Period," "Value," "Change," and "Change %" columns for these expenses. The page is part of a larger financial data platform, TradingView, providing financial information for GM0N.
Globus Medical Inc Class A Trade Ideas — XETR:GM0N
This article compiles various trade ideas and analyses for Globus Medical Inc Class A (GM0N/GMED) from different traders on TradingView. The analyses range from bullish outlooks based on strong earnings, technical breakouts, and long-term investment potential, to observations of short-term weakness and resistance levels. Several contributors highlight recent strong Q1 2026 earnings, share buyback programs, and technical patterns like bull flags, symmetrical triangles, and channel support as key factors influencing their trade strategies.
A Look At Globus Medical (GMED) Valuation After Recent Share Price Weakness
This article analyzes Globus Medical's (GMED) valuation following a recent share price decline, despite strong profitability. While the stock has fallen in the short term, longer-term returns remain positive. The analysis suggests GMED is potentially undervalued, with a fair value of $111.50 against its current trading price of $77.95, based on projections of continued innovation and growth, though integration challenges and sales cycles are noted as swing factors.
[8-K] GLOBUS MEDICAL INC Reports Material Event
Globus Medical, Inc. (GMED) filed an 8-K report detailing the outcomes of its 2026 Annual Meeting of Stockholders. Key approvals included an amendment to the 2021 Equity Incentive Plan to add 1,000,000 shares, increasing the total authorized shares to 12,000,000 Class A common shares. Stockholders also elected two Class II directors, ratified Deloitte & Touche LLP as the independent auditor for 2026, and approved the 2025 executive compensation on an advisory basis.
Responsive Playbooks and the GMED Inflection
Stock Traders Daily provides an AI-driven analysis for Globus Medical Inc. (NASDAQ: GMED), noting weak near-term sentiment but strong mid and long-term support signals. The report outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. It also offers multi-timeframe signal analysis to guide investors.
Number of shareholders of Globus Medical Inc Class A – BX:GMED
This article provides the number of shareholders for Globus Medical Inc Class A (BX:GMED). It focuses specifically on the company's financials, offering data related to the "Period Value Change" and "Change %" for shareholders. The information is sourced from financial data providers like ICE Data Services and FactSet.
Globus Medical (GMED) Is Up 7.4% After Q1 Beat And AI-Driven Margin Expansion Push - What's Changed
Globus Medical (GMED) saw a 7.4% increase after reporting a strong Q1, exceeding earnings and revenue expectations, expanding adjusted EBITDA margins, and raising full-year non-GAAP EPS guidance. The company's performance is attributed to the integration of NuVasive and Nevro, alongside the broad implementation of generative AI across its operations to drive efficiency and growth. This technology and M&A driven strategy has initiated a re-evaluation of its investment narrative and risk profile.
Is It Time To Reassess Globus Medical (GMED) After Recent Share Price Swings?
Globus Medical (GMED) has experienced recent share price volatility, with a 10.7% gain in the past week but a 10.7% drop over the last month. Despite these fluctuations, the stock has shown strong long-term performance and is currently assessed as undervalued by Simply Wall St's valuation models. Both a Discounted Cash Flow (DCF) analysis and a Price-to-Earnings (P/E) ratio comparison suggest significant undervaluation compared to its intrinsic value and industry peers.
Jim Cramer on Globus Medical: “There Is Not a Lot of Money to Be Made in This One”
Jim Cramer expressed a cautious outlook on Globus Medical (GMED), suggesting that the medical device group is currently unfavorable in the market and that there isn't much money to be made in GMED compared to other companies. Invesco Ltd.'s Q4 2025 investor letter noted that while Globus Medical faced challenges with recent acquisitions and supply chain issues, creating an attractive discount, they believe other AI stocks offer greater upside potential with less risk.
Globus Medical (GMED) Reports Next Week: Wall Street Expects Earnings Growth
Globus Medical (GMED) is projected to report a year-over-year increase in earnings and higher revenues for the quarter ended March 2026, with Wall Street analysts expecting $0.92 EPS and $730.32 million in revenue. However, the company currently has a Zacks Earnings ESP of -1.91% and a Zacks Rank of #1, making a conclusive prediction for an earnings beat difficult. Historically, Globus Medical has beaten consensus EPS estimates in three out of the last four quarters.
Is Reaffirmed 2026 Guidance and Capital Allocation Shifting the Investment Case for Globus Medical (GMED)?
Globus Medical (GMED) reported strong Q1 2026 sales and net income, reaffirming its full-year 2026 revenue guidance of US$3.18–3.22 billion. The company also reiterated its strategy for capital allocation, focusing on R&D, manufacturing, share repurchases, and selective M&A to support long-term profitable growth. This disciplined approach to capital allocation, coupled with solid guidance, influences the investment narrative despite potential risks from extended sales cycles in robotics and integration challenges.
Globus Medical (GMED) Valuation Check After Share Price Drop And Solid Quarterly Results
Globus Medical (GMED) shares have dropped significantly despite solid quarterly results, including higher sales and earnings, and reaffirmed full-year revenue guidance. The company is currently considered 31.3% undervalued at $76.64 against a narrative fair value of $111.50, driven by expectations of growing global demand for spine and orthopedic solutions. However, potential risks include prolonged sales cycles for robotics and integration issues from recent acquisitions.
The Technical Signals Behind (GMED) That Institutions Follow
This article from Stock Traders Daily discusses the technical signals for Globus Medical Inc. Class A (NASDAQ: GMED), noting weak near and mid-term sentiment despite a positive long-term outlook. It outlines three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis indicating support and resistance levels. The report emphasizes the use of AI models for optimizing position sizing and minimizing drawdown risk.
Globus Medical Reports First Quarter 2026 Results
Globus Medical (NYSE: GMED) announced strong first-quarter 2026 financial results, with worldwide net sales increasing by 27.0% to $759.9 million and GAAP diluted EPS rising by 66.6% to $0.90. The company reaffirmed its full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and updated its non-GAAP diluted EPS guidance to $4.70-$4.80. Growth was driven by share gains in core spine and expansion in Enabling Technologies, as well as the integration of Nevro.
Globus Medical (GMED) Net Margin Surge To 18.3% Tests Bullish Earnings Narratives
Globus Medical (GMED) has reported Q4 2025 revenue of US$826.4 million and basic EPS of US$1.05, with a trailing net margin surging to 18.3% from 4.1% a year prior. This significant margin expansion, along with strong year-over-year earnings growth, places the company's profitability and future sustainability in focus for investors. While bullish narratives point to efficiency gains, the current high margin challenges forecasts that anticipate a slight dip in future margins, raising questions about the repeatability of recent gains amidst integration risks and slower growth projections from skeptical analysts.
Globus Medical (GMED) posts 27% Q1 2026 sales growth and raises EPS outlook
Globus Medical announced strong financial results for Q1 2026, with worldwide net sales increasing by 27.0% year-over-year to $759.9 million. The company's GAAP net income rose 64.7% to $124.3 million, and non-GAAP diluted EPS increased by 64.7% to $1.12. Following these results, Globus Medical reaffirmed its 2026 revenue guidance and raised its full-year non-GAAP diluted EPS outlook, citing margin expansion and acquisition synergies.
Precision Trading with Globus Medical Inc. Class A (GMED) Risk Zones
This article provides a precision trading analysis for Globus Medical Inc. Class A (GMED), highlighting a weak near-term sentiment but strong long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths and support/resistance levels to assist traders in optimizing their strategies.
A Look At Globus Medical (GMED) Valuation As Shares Show Mixed Short Term Momentum
Globus Medical (GMED) shares recently closed at $90.18, showing mixed short-term returns but a strong 26.8% one-year total shareholder return. The company is considered undervalued with a fair value of $110.08, driven by innovation in robotics and minimally invasive procedures. Its P/E ratio of 22.7x is close to its fair ratio and below industry peers, suggesting a potential investment opportunity.
Vanguard reports 5,885,560 shares in Globus Medical (NYSE: GMED)
Vanguard Capital Management has reported a 5.22% beneficial ownership stake in Globus Medical (NYSE: GMED), totaling 5,885,560 shares. This disclosure, made via a Schedule 13G SEC filing, indicates that Vanguard holds sole voting power over 852,828 shares and sole dispositive power over all 5,885,560 shares. The filing underscores Vanguard's role as a significant institutional investor in Globus Medical, with holdings managed across various Vanguard funds and accounts.
Is It Time To Reassess Globus Medical (GMED) After Its Recent 1 Year Rally
This article analyzes Globus Medical (GMED) after its recent 1-year rally, using Discounted Cash Flow (DCF) and Price vs. Earnings (P/E) models to assess its current valuation. The DCF model suggests the stock is undervalued by 31.4% at approximately $90.74, implying an intrinsic value of $132.19 per share. However, its P/E ratio of 22.9x is slightly above its proprietary "Fair Ratio" of 22.4x, indicating it might be slightly overvalued by this metric.
